Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T : +91 40 2726 4141 F : +91 40 2726 3657



VLL\10\S 004\2020 Date: 23.01.2021

Listing Centre B S Li Limited P J Towers, Dalal Street Mumbai: 400001 Scrip Code No.524394 Asst Vice President National Stock Exchange of India Limited "Exchange Plaza", Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 **'I'rading Symbol: VIM'I'ALABS**

Dear Sirs,

Sub – Outcome of the Board Meeting held on 23.01.2021

Pursuant to Regulation 33 and 30 of SEBI (Listing obligations and disclosure requirements) 2015,

- Please find enclosed herewith Standalone and Consolidated Unaudited Financial Results for the third ended 31st December 2020, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company's website i.e., <u>http://www.vimta.com/financials</u>. Abridged financials are being published in the newspapers (copy enclosed).
- 2. We inform you that Company at its Board Meeting held on even date, has accepted the resignation of Shri. Amit Pathak, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company who has resigned due to his personal reasons, and he is being relieved with effect from closing of business hours on Thursday, 28th January 2021.
- 3. We further inform you that Board at its Meeting held on even date, has appointed Shri. Narahai Naidu, as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from Monday, 22nd February 2021 as per the provisions of section 203 of the Companies Act, 2013 read with Rules and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The details as per the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015 is given in Annexure-I.

The meeting commenced at 10:00 AM and ended at 12:30 PM

This is for your information and records.

Thanking you,

Yours faithfully for VIMTA LABSU Sujani Vasir Company Secreta

Encl: as above.

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com



1. The particulars for resignation of Shri. Amit Pathak as CFO and KMP, are as under:

Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation
Date of Cessation w.e.f	Closing of business hours on Thursday, 28th January 2021

2. The particulars for appointment of Shri. Narahai Naidu as CFO and KMP are as under:

Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
Date of Appointment w.e.f	Monday, 22 nd February 2021
Term of Appointment	Appointed as CFO and KMP of the Company by the Board of Directors on 23 rd January,2021 as per the provisions of Section 203 of the Companies Act, 2013
Brief Profile	Mr. Narahai Naidu is an experienced and result-oriented Professional and a Fellow Member of the Institute of Chartered Accountants of India and a Qualified Company Secretary; with over 14 years of experience in all facets of Financial Administration including Accounts & Audit, Financial Planning, Formulating Financial Policies & Processes, Strategy, Treasury & Fund Raising, Annual Operating Plan (AOP), MIS, Working Capital Management, Insurance, Taxation, Merger & Acquisition, Restructuring & Business
	 Transformation, Investor Relations, Enterprise Risk Management, Internal Audit, Revenue Assurance, Internal Financial Controls Implementation, Regulatory Compliances & Governance. Prior to joining Vimta Labs Limited, he worked in various capacities in different organisations. He is not related to the promoters or any member of the Board of directors or Key Managerial Personnel as defined under the Companying Act. 2013.
Disclosure of relationships between Directors (in case of a provintment of a Director)	the Companies Act, 2013 of Not Applicable

This is for your information and records.

Thanking you,

Yours faithfully, for VIMTA LAB BAD-51

Sujani Vasireddi **Company Secretary**

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T: +91 40 6740 4040 E: mdoffice@vimta.com URL: www.vimta.com

Limited Review Report on Unaudited Standalone Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

- We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company'), for the quarter ended 31 December 2020 and the year to date results for the period 01 April 2020 to 31 December 2020, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 23-01-2021

for GATTAMANENI & CO. Chartered Accountants Firm Regn.No.009303S) F.R.No: 93035 G. SRÍNIVASARAO Partner PED AC ICAI Ms. No.210535 UDIN: 21210535AAAABK3975

Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T : +91 40 2726 4141 F : +91 40 2726 3657



Statement of unaudited standalone financial results for the Quarter and Nine months ended December 31, 2020 (Amount in INR millions, except Earnings Per Share)

		Quarter Ended			Nine Months ended		Year Ended	
\$. No.	Particulars	31 Dec 20	30 Sep 20	31 Dec 19	31 Dec 20	31 Dec 19	31 Mar 20	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income from operations							
	(a) Revenue from operations	581.87	588.03	514.83	1,495.58	1,374.47	1.906.74	
	(b) Other income	3,04	0.37	8.35	5.72		1,806.74	
	Total Income	584.91	588.40	523.18	1,501.30	13 39	30.18	
			000110	525.10	1,501.50	1,307.00	1,030.92	
2	Expenses							
	(a) Cost of materials consumed and testing	155.25	168.13	142.24	411.35	402.07	533.81	
	expenditure					1.00000000		
	(b) Purchase of stock-in-trade	-	-	-	-			
	(c) Changes in inventories of work-in-progress	8.56	10.49	4.50	29.25	2.82	3.60	
	(d) Employee benefits expense	158.50	152.63	158.43	439.27	459.19	614.29	
1	(e) Finance costs	5.81	3.17	9.28	14.89	25.53	37.65	
	(f) Depreciation expense	57.31	57.80	52.73	171.50	156.62	209.22	
	(g) Other expenses	93.78	98.83	94.74	255.40	259.74	354.89	
	Total Expenses	479.21	491.05	461.92	1,321.66	1,305.97	1,753.46	
3	Profit/(Loss) before exceptional items and tax	105.70	97.35	61.26	179.64	81.89	83.46	
	[1-2]							
	Exceptional items		-				-	
5	Profit/(Loss) before tax [3-4]	105.70	97.35	61.26	179.64	81.89	83.46	
6	Tax expense							
0	(a) Current tax	24.40						
		26.60	27.60	22.80	54.20	34.45	33.61	
	(b) Taxes of earlier periods	-	-	(3.91)	-	(3.91)	(3.91	
	(c) Deferred tax (benefit)/expense	(1.02)	(4.01)	(4.75)	(9.69)	(16.50)	(15.51	
	Total Tax Expense	25.58	23.59	14.14	44.51	14.04	14.19	
7	Profit/(Loss) for the year (5-6)	80.12	73.76	47.12	135.13	67.85	69.27	
8	Other Comprehensive Income/(expense), net of							
	tax expenses							
	Items that will not be reclassified subsequently							
	to profit or loss :							
	(a) Re-measurements of net defined benefit	(0.65)	(0.65)	(1.03)	(1.95)	(3.05)	(2.53	
	liability							
	(b) Income tax relating to the items	0.16	0.17	0.26	0.49	0.77	0.64	
1	Total other comprehensive income, net of tax	(0.49)	(0.48)	(0.77)	(1.46)	(2.28)	(1.89)	
9	Total Comprehensive Income for the year	79.63	73.28	46.35	133.67	65.57	67.38	
(comprising Profit/(Loss) and other							
0	Comprehensive income for the year [7+8]							
10 F	Paid-up Equity Share Capital (Face value of	44.22	44.22	44.22	44.22	44.22	44.22	
	Rs.2/- per equity share)					11122	11.22	
1 0	Other Equity						1,685.37	
2 E	arnings per equity share (EPS) (Face value of							
F	Rs.2 per share)							
(a) Basic (INR)	3.62	3.34	2.13	6.11	3.07	3.13	
(b) Diluted (INR)	3.62	3.34	2.13	6.11	3.07	3.13	
(EPS for the quarter ended are not annualised)							





Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

Notes to the results :

- 1 The above unaudited standalone financial results for the quarter and nine months ended December 31, 2020 have been reviewed by the Audit Committee on January 22, 2021, approved by the Board in its meeting held on January 23, 2021 and the limited review of the same has been carried out by the statutory auditors. Auditors have expressed an unqualified report on the above results.
- 2 These unaudited financials results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Company has only one reportable segment namely 'Contract Research and Testing Services'.
- 4 Corresponding quarter/year to date/year end figures have been re-grouped/re-classified wherever necessary to conform to the classification of the current period.

For and on behalf of the Board of Directors of Vimta Labs Limited CIN: L24110TG1990PLC011977

-Harita Vasireddi

Managing Director

Place : Hyderabad, INDIA Date : January 23, 2021







Vimta Labs Limited **Registered** Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, Telangana, India T:+91 40 2726 4141 F:+91 40 2726 3657



Statement of unaudited standalone financial results for the Quarter and Nine months ended December 31, 2020 (Amount in INR millions, except Earnings Per Share)

S. No.	Particulars		Quarter Endec	1	Nine Mon	ths ended	Year ended
		31 Dec 20	30 Sep 20	31 Dec 19	31 Dec 20	31 Dec 19	31 Mar 20
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 2	Total Income from Operations Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary	581.87 105.70	588.03 97.35	514.83 61.26	1,495.58 179.64	1,374.47 81.89	1,806.74 83.46
	Items) Net Profit / (Loss) for the period before I ax (after Exceptional and/or Extraordinary Items)	105.70	97.35	61.26	179.64	81.89	83.46
	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	80.12	73.76	47.12	135.13	67.85	69.27
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income	79.63	73.28	46.35	133.67	65.57	67.38
6 7	(after tax)] Equity Share Capital Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	44.22	44.22	44.22	44.22	44.22	44.22 1,685.37
1	Earnings Per share (of Rs.2/- each) (for continuing and discontinued Operations) I. Basic (INR) 2. Diluted (INR)	3.62 3.62	3.34 3.34	2.13 2.13	6.11 6.11	3.07 3.07	3.13 3.13

The above is an extract of the detailed format of Quarterly and Nine months Financial Results filed with the Stock Exchanges under 1 Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).

- The above unaudited financial results of the company for the quarter and nine months ended December 31, 2020 have been reviewed 2 by the Audit Committee on January 22, 2021, approved by the Board of Directors at their meeting held on January 23, 2021 and the limited review of the same has been carried out by the statutory auditors. Auditors have expressed an unqualified report on the above results.
- Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary. 3

For and on behalf of the Board of Directors of Vimta Labs Limited CIN: L24110TG1990PLC011977

Harita Vasireddi Managing Director

Place : Hyderabad, INDIA Date : January 23, 2021





Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T: +91 40 6740 4040 E: mdoffice@vimta.com URL: www.vimta.com

Limited Review Report on Unaudited Consolidated Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Holding Company') and M/s. EMTAC Laboratories Private Limited, wholly owned subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended 31 December 2020 and the year to date results for the period 01 April 2020 to 31 December 2020, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.



We also performed procedures in accordance with Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 23-01-2021

for GATTAMANENI & CO. Chartered Accountants (Firm Regn.No.009303S)

G. SRIŇIVASARAO Partner ICAI Ms. No.210535 UDIN: 21210535AAAABL3199

F.R.No: 93039



Statement of unaudited consolidated financial results for the Quarter and Nine months ended December 31, 2020
(Amount in INR millions, except Earnings Per Share)

No	Particulars		r Ended	Nine Months Ended	Year ended
. NO	Particulars	31 Dec 20 (Unaudited)	30 Sep 20 (Unaudited)	31 Dec 20 (Unaudited)	31 Mar 20 (Audited)
				(onduced)	(Addited)
1	Income from operations				
	(a) Revenue from operations	586.76	593.82	1,508.37	1,807
	(b) Other income	3.24	0.35	5.94	30
	Total Income	590.00	594,17	1,514.31	1,837.
2	Expenses				
	(a) Cost of materials consumed and tosting	154 45	1.00.10		
	expenditure	156.15	169.1Z	413.67	533
	(b) Purchase of stock-in-trade				
	(c) Changes in inventories of work-in-progress	-	-	-	
	(d) Employee benefits expense	8.56	10.49	29.25	3
	(e) Finance costs	159.92	153.99	443.03	614
		5.81	3.17	14.89	37
	(f) Depreciation expense	57.67	58.14	172.54	209
	(g) Other expenses	95.58	100.30	259.74	355
	Total Expenses	483.69	495.21	1,333.12	1,754
	Profit/(Loss) before exceptional items and tax [1-	106.31	98.96	181.19	82
	2]				C.L
	Exceptional items	-	-	-	
	Profit/(Loss) before tax [3-4]	106.31	98.96	181.19	82.
	Tax expense				
	(a) Current tax	26,60	27.60	54.00	
	(b) Taxes of earlier periods	20.00	27.00	54.20	33.
	(c) Deferred tax (benefit)/expense	(0.02)		-	(3.
	Total Tax Expense	(0.98)	(4.01)	(9.64)	(15.
			23.37	44.30	14.
F	Profit/(Loss) for the year (5-6)	80.69	75.37	136.63	68.4
0	Other Comprehensive Income/(expense), net of				
	ax expenses				
1	tems that will not be reclassified subsequently to				
	profit or loss :				
	a) Re-measurements of net defined benefit	(0.45)	(0.(5)		
	iability	(0.65)	(0.65)	(1.95)	(2.5
(1	b) Income tax relating to the items	0.17	0.17	0.49	0.6
Т	otal other comprehensive income, net of tax	(0.48)	(0.48)	(1.46)	(1.8
	-				(1.,
T	otal Comprehensive Income for the year	80.21	74.89	135.17	<i>(((</i>
(0	comprising Profit/(Loss) and other Comprehensive	UULI	/4.07	155.17	66.5
ir	ncome for the year [7+8]				
Pa					
	aid-up Equity Share Capital (Face value of Rs.2/-	44.22	44.22	44.22	44.2
P	er equity share)				
0	ther Equity				1,684.5
E	Proints por aquitu abaya (FDC) (Face a la secondaria				.,
	arnings per equity share (EPS) (Face value of Rs.2 er share)				
1.	· · · · · · · · · · · · · · · · · · ·				
) Basic (INR)	3.65	3.41	6.18	3.1
) Diluted (INR)	3.65	7 41	6.40	
	PS for the quarter ended are not annualised)	3.05	3.41	6.18	3.10



A

Aline WIM TA LABOR

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

Notes to the results :

- The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2020 have been reviewed by 1 the Audit Committee on January 22, 2021, approved by the Board in its meeting held on January 23, 2021 and the limited review of the same has been carried out by the statutory auditors. Auditors have expressed an unqualified report on the above results.
- These unaudited financials results of the Group are prepared in accordance with the Indian Accounting Standards prescribed under 2 section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating 3 Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'.
- As there were no consolidated financial results in the corresponding previous periods, results of such corresponding previous periods 4 are not presented.

For and on behalf of the Board of Directors of Vimta Labs Limited

CIN: L24110TG1990PLC011977 ٢Δ 1 er HND Harita Vasireddi Managing Director

Place : Hyderabad, INDIA Date : January 23, 2021







Statement of unaudited consolidated financial results for the Quarter and Nine months ended Decer (Amount in INR millions, except Farriage Dec State	mber 31, 2020
(Amount in INR millions, except Earnings Per Share)	1001 31, 2020

	Particulars	Quarter	Ended	Nine Months Ended	N
		31 Dec 20 (Unaudited)	30 Sep 20 (Unaudited)	31 Dec 20 (Unaudited)	Year ended 31 Mar 20 (Audited)
1 2	Total Income from Operations Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	586.76 106.31	593.82 98.96	1,508.37 181.19	1,807.1
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	106.31	98.96	181.19	82.7
1	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	80.69	75.37	136.63	68.4
	Total Comprehensive Income for the period Comprising Profit / (Loss) for the period after tax) and other Comprehensive Income after tax)]	80.21	74.89	135.17	66.50
E R sl pi	quite (ax)] quity Share Capital eserves (excluding Revaluation Reserve) as hown in the Audited Balance Sheet of the revious year arnings Per share (of Rs.2/- each) (for	44.22	44.22	44.22	44.22 1,684.55
1.	Diluted (INR)	3.65 3.65	3.41 3.41	6.18 6.18	3.10 3.10

Note :

- 1 The above is an extract of the detailed format of Quarterly and Nine months Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
- 2 The above unaudited consolidated financial results of the group for the quarter and nine months ended December 31, 2020 have been reviewed by the Audit Committee on January 22, 2021, approved by the Board of Directors at their meeting held on January report on the above results.
 3 Figures of the previous periods have been approached by the statutory auditors. Auditors have expressed an unqualified
- 3 Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of Vimta Labs Limited

CIN: L24110TG1990PLC011977

Harita Vasireddi Managing Director

Place : Hyderabad, INDIA Date : January 23, 2021



